Quantcast

Latest Interferon beta-1a Stories

2008-07-16 09:01:19

Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial. Bravo is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex. The Bravo trial, which was initiated in April, 2008, aims to enroll approximately 1,200...

2006-06-05 16:35:00

By Susan Heavey WASHINGTON (Reuters) - U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease. Three patients taking the drug, made by Biogen Idec Inc. and distributed by Elan Corp., had developed progressive multifocal leukoencephalopathy (PML). Two of them died. Food and Drug Administration officials, who faced calls from...

2006-05-31 02:13:50

LOS ANGELES (Reuters) - Teva Pharmaceutical Industries Ltd. said on Wednesday that its multiple sclerosis drug Copaxone was shown in a clinical trial to be effective in patients who had stopped responding to Avonex, a competing drug made by Biogen Idec. Israel-based Teva said the study of patients with relapsing-remitting MS found that Copaxone reduced their annual relapse rate by an additional 57 percent over Avonex, and that neurologic disability did not worsen in 86 percent of...

2006-04-05 16:15:00

By Deena Beasley LOS ANGELES (Reuters) - A high dose of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone is more effective at limiting relapses and brain lesions than the standard dose, without more side effects, researchers said on Wednesday. "For some people a higher dose may work better," said Dr. Jeffrey Cohen of the Cleveland Clinic's MS research center and lead investigator of a small nine-month trial comparing the two doses. The study, funded by Israel-based Teva,...

2005-09-16 09:49:18

By Julie Steenhuysen and Sitaraman Shankar CHICAGO/FRANKFURT (Reuters) - A drug from Genzyme Corp. and Schering helped reduce the risk of relapses in multiple sclerosis patients, but caused a serious side effect in three cases that led to a death, the companies said on Friday. Genzyme and Schering have suspended dosing in the trial for Campath, which is approved to treat a form of leukemia, while they work closely with U.S. regulators and clinical investigators "to ensure that a...

2004-11-27 12:00:07

WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc. and Irish drug maker Elan Corp. -- is known chemically as natalizumab. During clinical trials, it was called Antegren, but in the Food and Drug Administration announcement, the name was changed to Tysabri....

2004-11-26 18:00:09

FRIDAY, Nov. 26 (HealthDayNews) -- The U.S. Food and Drug Administration has approved Tysabri (natalizumab) as a new treatment for multiple sclerosis. The incurable nervous system disease affects about 350,000 Americans. The drug, known as a humanized monoclonal antibody, appears to work by preventing immune cells from migrating from the bloodstream to the brain, where they cause inflammation and lead to nerve fiber damage, its two manufacturers said in a statement. The medication is...

2004-11-26 06:00:07

WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc. and Irish drug maker Elan Corp. -- is known chemically as natalizumab. During clinical trials, it was called Antegren, but in the Food and Drug Administration announcement, the name was changed to Tysabri....


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related